Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lobe Sciences ( (TSE:LOBE) ) has provided an update.
Lobe Sciences has launched a non-brokered private placement of 14,615,384 common shares at $0.065 per share, aiming to raise approximately $950,000 in gross proceeds. The company plans to direct the funds toward working capital and general corporate expenses, with the financing still contingent on regulatory approvals and subject to a statutory four-month hold period in Canada.
The raise comes as Lobe continues to build out its portfolio of neuroscience-focused drug candidates, notably via its 64%-owned Cynaptec unit and its oral psilocin analog L-130, which is being developed for chronic cluster headaches and potentially substance use disorders. By securing additional capital without using a broker, Lobe seeks to strengthen its balance sheet and maintain momentum in late-stage development of its psychedelic-derived therapies within a competitive neurological and psychiatric treatment landscape.
The most recent analyst rating on (TSE:LOBE) stock is a Hold with a C$0.06 price target. To see the full list of analyst forecasts on Lobe Sciences stock, see the TSE:LOBE Stock Forecast page.
Spark’s Take on LOBE Stock
According to Spark, TipRanks’ AI Analyst, LOBE is a Neutral.
The score is held down primarily by very weak financial performance (near-zero TTM revenue, persistent losses, and ongoing cash burn), partially offset by modest leverage and improved equity. Technical indicators are mildly supportive, but valuation remains constrained by unprofitability (negative P/E) and no dividend yield data.
To see Spark’s full report on LOBE stock, click here.
More about Lobe Sciences
Lobe Sciences Ltd. is a biopharmaceutical company focused on advancing therapies for diseases with unmet medical needs. Through subsidiaries including majority-owned Cynaptec Pharmaceuticals Inc. and wholly owned Applied Lipid Technologies Inc., it targets neurological and psychiatric disorders using novel compounds such as its patented psilocin analog L-130.
Average Trading Volume: 117,035
Technical Sentiment Signal: Buy
Current Market Cap: C$21.56M
See more data about LOBE stock on TipRanks’ Stock Analysis page.